VISTAGEN THERAPEUTICS, INC. Amortization of Debt Discount (Premium)
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Amortization of Debt Discount (Premium) of $0 for the 9-month period ending 2016-12-31, per its 10-Q filed 2017-02-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2017-02-13
- VISTAGEN THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2016-12-31 was $0.00.
- VISTAGEN THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2016-09-30 was $0.00, a 100.00% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2016-06-30 was $0.00, a 100.00% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. amortization of debt discount (premium) for fiscal 2015 was $3.37M, a 426.88% increase from fiscal 2014.
- VISTAGEN THERAPEUTICS, INC. amortization of debt discount (premium) for fiscal 2014 was $640.00K, a 151.18% increase from fiscal 2013.
- VISTAGEN THERAPEUTICS, INC. amortization of debt discount (premium) for fiscal 2013 was $254.80K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month | Amortization of Debt Discount (Premium) 181 month | Amortization of Debt Discount (Premium) 184 month |
|---|---|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-02-13 | $0.00 derived: sum of 2 quarters · filed 2017-02-13 | $0.00 10-Q · filed 2017-02-13 | |||
| 2016-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-11-14 | $0.00 10-Q · filed 2016-11-14 | ||||
| 2016-06-30 | $0.00 10-Q · filed 2016-08-12 | |||||
| 2015-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-02-13 | $14.00K derived: sum of 2 quarters · filed 2017-02-13 | $564.80K 10-Q · filed 2017-02-13 | $2.64M derived: sum of 4 quarters · filed 2017-02-13 | ||
| 2015-09-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-11-14 | $564.80K 10-Q · filed 2016-11-14 | $2.64M derived: sum of 3 quarters · filed 2016-11-14 | $3.14M derived: sum of 4 quarters · filed 2016-11-14 | ||
| 2015-06-30 | $550.80K 10-Q · filed 2016-08-12 | $2.63M derived: sum of 2 quarters · filed 2016-08-12 | $3.12M derived: sum of 3 quarters · filed 2016-08-12 | $3.44M derived: sum of 4 quarters · filed 2016-08-12 | ||
| 2015-03-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2015-06-29 | $2.57M derived: sum of 2 quarters · filed 2016-02-16 | $2.89M derived: sum of 3 quarters · filed 2016-02-16 | $3.37M 10-K · filed 2015-06-29 | ||
| 2014-12-31 | $495.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-02-16 | $812.80K derived: sum of 2 quarters · filed 2016-02-16 | $1.29M 10-Q · filed 2016-02-16 | $1.58M derived: sum of 4 quarters · filed 2016-02-16 | ||
| 2014-09-30 | $317.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-11-16 | $799.00K 10-Q · filed 2015-11-16 | $1.08M derived: sum of 3 quarters · filed 2015-11-16 | $1.24M derived: sum of 4 quarters · filed 2015-11-16 | ||
| 2014-06-30 | $481.90K 10-Q · filed 2015-08-14 | $765.80K derived: sum of 2 quarters · filed 2015-08-14 | $919.90K derived: sum of 3 quarters · filed 2015-08-14 | $1.03M derived: sum of 4 quarters · filed 2015-08-14 | ||
| 2014-03-31 | $283.90K derived: 10-K 12 month − 10-Q 9 month · filed 2015-06-29 | $438.00K derived: sum of 2 quarters · filed 2015-06-29 | $546.00K derived: sum of 3 quarters · filed 2015-06-29 | $640.00K 10-K · filed 2015-06-29 | $5.32M 10-K · filed 2014-06-25 | |
| 2013-12-31 | $154.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-02-17 | $262.10K derived: sum of 2 quarters · filed 2015-02-17 | $356.10K 10-Q · filed 2015-02-17 | $258.70K derived: sum of 4 quarters · filed 2015-02-17 | $5.03M 10-Q · filed 2014-02-14 | |
| 2013-09-30 | $108.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-11-19 | $202.00K 10-Q · filed 2014-11-19 | $104.60K derived: sum of 3 quarters · filed 2014-11-19 | |||
| 2013-06-30 | $94.00K 10-Q · filed 2014-08-12 | -$3.40K derived: sum of 2 quarters · filed 2014-08-12 | ||||
| 2013-03-31 | -$97.40K derived: 10-K 12 month − 10-Q 9 month · filed 2014-06-25 | $254.80K 10-K · filed 2014-06-25 | ||||
| 2012-12-31 | $352.20K 10-Q · filed 2014-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |